Q-omics provides the consensus-scored CAPN5 profile across patient tissues and cancer cell-line models. CAPN5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CAPN5 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CAPN5 RNA expression shows 18,422 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KICH, and KIRP as cancer lineages where CAPN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPN5 survival associations across molecular data types. CAPN5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPN5 RNA expression–survival associations across cancer types. High CAPN5 expression shows unfavorable associations in KICH, MESO, UCEC, LGG and LUSC, but favorable associations in BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CAPN5 RNA expression.
This table summarizes CAPN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CAPN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPN5 shows lower tumor expression in KICH, HNSC, KIRC, COAD and READ and higher tumor expression in LUAD. The KICH box plot shows higher CAPN5 RNA expression in normal versus tumor tissue (log2 FC = −1.885, t-test p < 0.001).
This table shows molecular features associated with CAPN5 in patient tissues and cancer cell lines. In patient samples, CAPN5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
